Pulse Biosciences announced it has enhanced its executive leadership team.

Pulse Biosciences宣布增强了其执行领导团队。

Burke T. Barrett has been appointed the company’s new president and CEO, effective immediately. Pulse Bio also named former president and CEO Kevin Danahy as its new chief commercial officer. Danahy will now focus on leading pilot launch of the company’s recently FDA-cleared CellFX nsPFA (nanosecond pulsed field ablation) percutaneous electrode system..

伯克·巴雷特（BurkeT.Barrett）被任命为公司新任总裁兼首席执行官，立即生效。Pulse Bio还任命前总裁兼首席执行官凯文·达纳希（KevinDanahy）为其新任首席商务官。Danahy现在将专注于领导该公司最近FDA批准的CellFX nsPFA（纳秒脉冲场消融）经皮电极系统的试点启动。。

“Burke is a very talented executive, who has demonstrated strong leadership and operational acumen throughout his medical device career. With Pulse’s focus on bringing the patient and physician friendly benefits of Nanosecond Pulse Field Ablation into electrophysiology and cardiac surgery, we are thrilled to have someone with Burke’s industry stature and expertise lead team Pulse,” said Robert W.

“伯克（Burke）是一位非常有天赋的高管，在他的医疗器械职业生涯中表现出强大的领导力和运营敏锐度。Pulse专注于将纳秒脉冲场消融对患者和医生的友好益处带入电生理学和心脏外科，我们很高兴有一位具有伯克行业地位和专业知识的人领导Pulse团队，”罗伯特·W。

Duggan, executive chairman of Pulse Biosciences. “Together with Burke’s expertise and Kevin leading as chief commercial officer, Pulse Biosciences is positioned to unlock the full potential of our proprietarily designed and engineered CellFX nsPFA energy delivery system and its three novel proprietary end-effector devices.”.

Duggan，Pulse Biosciences执行主席。“Pulse Biosciences凭借伯克（Burke）的专业知识和首席商务官凯文（Kevin）的领导，致力于挖掘我们经过适当设计和工程改造的CellFX nsPFA能量输送系统及其三种新型专有末端效应器设备的全部潜力。”。

Barrett has over 35 years of experience in the medical device industry. He spent 18 years at CardioFocus in positions of increasing responsibility and was a member of the team that built a pioneering electrophysiology ablation device and global commercial company. Barrett left the company as CEO and president..

巴雷特在医疗器械行业拥有超过35年的经验。他在CardioFocus工作了18年，担任着越来越重要的职位，并且是一家开创性的电生理消融设备和全球商业公司的团队成员。巴雷特离开公司担任首席执行官和总裁。。

Prior to CardioFocus, Barrett served on teams that took two companies public: Biofield Corp. and Cyberkinetics Neurotechnology Systems. He’s also been an officer at public companies Cyberonics (VP of business and technology development) and Cyberkinetics (VP of clinical operations).

在CardioFocus之前，巴雷特曾供职于两家公司上市的团队：Biofield Corp.和Cyberkinetics Neurotechnology Systems。他还曾任上市公司Cyberonics（业务和技术开发副总裁）和Cyberkinetics（临床运营副总裁）的高管。

Barrett was also an active member of the U.S. Food and Drug Administration (FDA)’s Circulatory System Medical Devices Advisory Panel for four years.

巴雷特也是美国食品和药物管理局（FDA）循环系统医疗器械咨询小组的活跃成员，任期四年。

He is currently on the board of directors of VDI Technologies, as well.

他目前也是VDI Technologies的董事会成员。

“Joining Team Pulse at this important time for the Company represents a unique and exciting opportunity to make a material difference for the betterment of patients, physicians, and care givers,” said Barrett. “I’ve spent the majority of my career working closely with electrophysiologists and introducing them to novel technologies, and I believe that CellFX nsPFA energy has the potential to advance the standard of care for the treatment of atrial fibrillation and additional disease states.

巴雷特说：“在公司的这个重要时刻加入团队脉搏代表着一个独特而令人兴奋的机会，可以为患者、医生和护理人员的改善带来实质性的改变。”。“我职业生涯的大部分时间都与电生理学家密切合作，并向他们介绍新技术，我相信CellFX nsPFA energy有可能提高治疗心房颤动和其他疾病状态的护理标准。

The preclinical and initial clinical data provides a solid foundation to build upon, as we continue to seek regulatory approvals in the United States and other parts of the world. I look forward to working closely with the talented executive team and Board of Directors as Pulse enters this next phase of growth.”.

随着我们继续在美国和世界其他地区寻求监管部门的批准，临床前和初始临床数据为我们奠定了坚实的基础。随着Pulse进入下一个增长阶段，我期待着与才华横溢的执行团队和董事会密切合作。”。

“It is an honor to be a key team member in leading Pulse Biosciences into this iconic and historic opportunity,” added Kevin Danahy. “I look forward to working closely with Burke in both learning from his vast experience as well as sharing my knowledge and experience with him as Team Pulse Biosciences launches our novel CellFX nsPFA Percutaneous Electrode System and achieves meaningful progress toward commercial opportunities in cardiac ablation.” .

凯文·达纳希补充道：“很荣幸能够成为领导Pulse Biosciences进入这一标志性和历史性机遇的关键团队成员。”。“随着Team Pulse Biosciences推出我们的新型CellFX nsPFA经皮电极系统，并在心脏消融的商业机会方面取得有意义的进展，我期待着与Burke密切合作，学习他的丰富经验，并与他分享我的知识和经验。”。